Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Of The Week: Merck/Chimerix, Merck/Yamasa, CoDa/Rusnano/Domain

Executive Summary

AstraZeneca has done a good job of preparing investors for revenue declines due to its patent cliff, but Wall Street thinks the pharma will need to undertake significant M&A activity to remain viable.

You may also be interested in...



CoDa Therapeutics Closes B Round with $40 Million from Rusnano/ Domain-Led Syndicate

Wound healing company CoDa Therapeutics is the first Domain portfolio company to benefit from the venture capital firm’s new, $760 million partnership with Russian sovereign fund Rusnano

Chimerix Chooses Merck As HIV Partner, Keeps Broad-Spectrum Antiviral

The North Carolina-based start-up strikes a global deal for a Phase I HIV drug, which will allow it to fund late-stage trials on another lipid-antiviral conjugate.

In A Changing Diabetes Drug Market, Who Will Come Out On Top?

New treatments for Type 2 diabetes are driving the optimism underlying Bristol and AstraZeneca’s proposed acquisition for Amylin and are leading to a re-alignment of allies and competitors focused on the disease. Companies are enthusiastic about the vast opportunity, yet worried about the costs and risks of full-scale commitment to it.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS054635

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel